Now showing items 21-40 of 757

    • Adherence to Guidelines for Adult (Non-GIST) Soft Tissue Sarcoma in the Netherlands: A Plea for Dedicated Sarcoma Centers. 

      Hoekstra, HJ; Haas, RLM; Verhoef, C; Suurmeijer, AJH; van Rijswijk, CSP; Bongers, BGH; van der Graaf, WT; Ho, VKY (2017-10)
      Optimal management of soft tissue sarcoma (STS) remains a challenge. A nationwide survey assessed the quality of STS care in the Netherlands, thereby aiming to identify potentialities for improvement through more centralized ...
    • Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial. 

      Corrie, PG; Marshall, A; Nathan, PD; Lorigan, P; Gore, M; Tahir, S; Faust, G; Kelly, CG; Marples, M; Danson, SJ; Marshall, E; Houston, SJ; Board, RE; Waterston, AM; Nobes, JP; Harries, M; Kumar, S; Goodman, A; Dalgleish, A; Martin-Clavijo, A; Westwell, S; Casasola, R; Chao, D; Maraveyas, A; Patel, PM; Ottensmeier, CH; Farrugia, D; Humphreys, A; Eccles, B; Young, G; Barker, EO; Harman, C; Weiss, M; Myers, KA; Chhabra, A; Rodwell, SH; Dunn, JA; Middleton, MR; AVAST-M Investigators; Nathan, P; Lorigan, P; Dziewulski, P; Holikova, S; Panwar, U; Tahir, S; Faust, G; Thomas, A; Corrie, P; Sirohi, B; Kelly, C; Middleton, M; Marples, M; Danson, S; Lester, J; Marshall, E; Ajaz, M; Houston, S; Board, R; Eaton, D; Waterston, A; Nobes, J; Loo, S; Gray, G; Stubbings, H; Gore, M; Harries, M; Kumar, S; Goodman, A; Dalgleish, A; Martin-Clavijo, A; Marsden, J; Westwell, S; Casasola, R; Chao, D; Maraveyas, A; Marshall, E; Patel, P; Ottensmeier, C; Farrugia, D; Humphreys, A; Eccles, B; Dega, R; Herbert, C; Price, C; Brunt, M; Scott-Brown, M; Hamilton, J; Hayward, RL; Smyth, J; Woodings, P; Nayak, N; Burrows, L; Wolstenholme, V; Wagstaff, J; Nicolson, M; Wilson, A; Barlow, C; Scrase, C; Podd, T; Gonzalez, M; Stewart, J; Highley, M; Wolstenholme, V; Grumett, S; Goodman, A; Talbot, T; Nathan, K; Coltart, R; Gee, B; Gore, M; Farrugia, D; Martin-Clavijo, A; Marsden, J; Price, C; Farrugia, D; Nathan, K; Coltart, R; Nathan, K; Coltart, R (2018-08)
      Background:Bevacizumab is a recombinant humanised monoclonal antibody to vascular endothelial growth factor shown to improve survival in advanced solid cancers. We evaluated the role of adjuvant bevacizumab in melanoma ...
    • Adjuvant chemotherapy may improve disease-free survival in patients with rectal cancer positive for MRI-detected extramural venous invasion following chemoradiation. 

      Chand, M; Rasheed, S; Heald, R; Swift, I; West, N; Rao, S; Tekkis, P; Brown, G (2017-06)
      MRI-detected extramural venous invasion (mrEMVI) is a poor prognostic factor in rectal cancer. Preoperative chemoradiotherapy (CRT) can cause regression in the severity of EMVI and subsequently improve survival whereas ...
    • Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. 

      Long, GV; Hauschild, A; Santinami, M; Atkinson, V; Mandalà, M; Chiarion-Sileni, V; Larkin, J; Nyakas, M; Dutriaux, C; Haydon, A; Robert, C; Mortier, L; Schachter, J; Schadendorf, D; Lesimple, T; Plummer, R; Ji, R; Zhang, P; Mookerjee, B; Legos, J; Kefford, R; Dummer, R; Kirkwood, JM (2017-11)
      BACKGROUND:Combination therapy with the BRAF inhibitor dabrafenib plus the MEK inhibitor trametinib improved survival in patients with advanced melanoma with BRAF V600 mutations. We sought to determine whether adjuvant ...
    • Adjuvant Dendritic Cell Vaccination in High-Risk Uveal Melanoma. 

      Bol, KF; van den Bosch, T; Schreibelt, G; Mensink, HW; Keunen, JEE; Kiliç, E; Japing, WJ; Geul, KW; Westdorp, H; Boudewijns, S; Croockewit, SAJ; van Rossum, MM; de Goede, AL; Naus, NC; van der Graaf, WTA; Gerritsen, WR; de Klein, A; Punt, CJA; Figdor, CG; Cohen, VM; Paridaens, D; de Vries, IJM (2016-10)
    • Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. 

      Weber, J; Mandala, M; Del Vecchio, M; Gogas, HJ; Arance, AM; Cowey, CL; Dalle, S; Schenker, M; Chiarion-Sileni, V; Marquez-Rodas, I; Grob, J-J; Butler, MO; Middleton, MR; Maio, M; Atkinson, V; Queirolo, P; Gonzalez, R; Kudchadkar, RR; Smylie, M; Meyer, N; Mortier, L; Atkins, MB; Long, GV; Bhatia, S; Lebbé, C; Rutkowski, P; Yokota, K; Yamazaki, N; Kim, TM; de Pril, V; Sabater, J; Qureshi, A; Larkin, J; Ascierto, PA; CheckMate 238 Collaborators (2017-11)
      BACKGROUND:Nivolumab and ipilimumab are immune checkpoint inhibitors that have been approved for the treatment of advanced melanoma. In the United States, ipilimumab has also been approved as adjuvant therapy for melanoma ...
    • Adolescent and young adult (AYA) lymphoma survivors report lower health-related quality of life compared to a normative population: results from the PROFILES registry. 

      Husson, O; Prins, JB; Kaal, SEJ; Oerlemans, S; Stevens, WB; Zebrack, B; van der Graaf, WTA; van de Poll-Franse, LV (2017-02)
      Trying to simultaneously achieve developmental milestones and cope with a life-threatening disease may place adolescents and young adults (AYAs) at risk for impaired health-related quality of life (HRQoL) later in life. ...
    • Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW. 

      Muro, K; Cho, JY; Bodoky, G; Goswami, C; Chao, Y; Dos Santos, LV; Shimada, Y; Topuzov, E; Van Cutsem, E; Tabernero, J; Zalcberg, J; Chau, I; Cascinu, S; Cheng, R; Hsu, Y; Emig, M; Orlando, M; Fuchs, C (2018-04)
      REGARD and RAINBOW were global, phase 3, randomized, double-blind trials of second-line ramucirumab for metastatic gastric or gastroesophageal junction adenocarcinoma. Exploratory subgroup analyses were described to assess ...
    • Age-related sarcoma patient experience: results from a national survey in England. 

      Younger, E; Husson, O; Bennister, L; Whelan, J; Wilson, R; Roast, A; Jones, RL; van der Graaf, WT (2018-10-17)
      BACKGROUND:Sarcomas are rare, heterogeneous tumours affecting patients of any age. Previous surveys describe that sarcoma patients report a significantly worse experience than those with common cancers. Consequently, Sarcoma ...
    • Age-specific genome-wide association study in glioblastoma identifies increased proportion of 'lower grade glioma'-like features associated with younger age. 

      Ostrom, QT; Kinnersley, B; Armstrong, G; Rice, T; Chen, Y; Wiencke, JK; McCoy, LS; Hansen, HM; Amos, CI; Bernstein, JL; Claus, EB; Eckel-Passow, JE; Il'yasova, D; Johansen, C; Lachance, DH; Lai, RK; Merrell, RT; Olson, SH; Sadetzki, S; Schildkraut, JM; Shete, S; Rubin, JB; Andersson, U; Rajaraman, P; Chanock, SJ; Linet, MS; Wang, Z; Yeager, M; GliomaScan consortium; Houlston, RS; Jenkins, RB; Wrensch, MR; Melin, B; Bondy, ML; Barnholtz-Sloan, JS (2018-11)
      Glioblastoma (GBM) is the most common malignant brain tumor in the United States. Incidence of GBM increases with age, and younger age-at-diagnosis is significantly associated with improved prognosis. While the relationship ...
    • AKT Inhibition in Solid Tumors With AKT1 Mutations. 

      Hyman, DM; Smyth, LM; Donoghue, MTA; Westin, SN; Bedard, PL; Dean, EJ; Bando, H; El-Khoueiry, AB; Pérez-Fidalgo, JA; Mita, A; Schellens, JHM; Chang, MT; Reichel, JB; Bouvier, N; Selcuklu, SD; Soumerai, TE; Torrisi, J; Erinjeri, JP; Ambrose, H; Barrett, JC; Dougherty, B; Foxley, A; Lindemann, JPO; McEwen, R; Pass, M; Schiavon, G; Berger, MF; Chandarlapaty, S; Solit, DB; Banerji, U; Baselga, J; Taylor, BS (2017-07)
      Purpose AKT1 E17K mutations are oncogenic and occur in many cancers at a low prevalence. We performed a multihistology basket study of AZD5363, an ATP-competitive pan-AKT kinase inhibitor, to determine the preliminary ...
    • Alcohol consumption and prostate cancer incidence and progression: A Mendelian randomisation study. 

      Brunner, C; Davies, NM; Martin, RM; Eeles, R; Easton, D; Kote-Jarai, Z; Al Olama, AA; Benlloch, S; Muir, K; Giles, G; Wiklund, F; Gronberg, H; Haiman, CA; Schleutker, J; Nordestgaard, BG; Travis, RC; Neal, D; Donovan, J; Hamdy, FC; Pashayan, N; Khaw, K-T; Stanford, JL; Blot, WJ; Thibodeau, S; Maier, C; Kibel, AS; Cybulski, C; Cannon-Albright, L; Brenner, H; Park, J; Kaneva, R; Batra, J; Teixeira, MR; Pandha, H; PRACTICAL Consortium,; Zuccolo, L (2017-01)
      Prostate cancer is the most common cancer in men in developed countries, and is a target for risk reduction strategies. The effects of alcohol consumption on prostate cancer incidence and survival remain unclear, potentially ...
    • ALPK1 hotspot mutation as a driver of human spiradenoma and spiradenocarcinoma. 

      Rashid, M; van der Horst, M; Mentzel, T; Butera, F; Ferreira, I; Pance, A; Rütten, A; Luzar, B; Marusic, Z; de Saint Aubain, N; Ko, JS; Billings, SD; Chen, S; Abi Daoud, M; Hewinson, J; Louzada, S; Harms, PW; Cerretelli, G; Robles-Espinoza, CD; Patel, RM; van der Weyden, L; Bakal, C; Hornick, JL; Arends, MJ; Brenn, T; Adams, DJ (2019-05-17)
      Spiradenoma and cylindroma are distinctive skin adnexal tumors with sweat gland differentiation and potential for malignant transformation and aggressive behaviour. We present the genomic analysis of 75 samples from 57 ...
    • Alternative splicing in prostate cancer. 

      Paschalis, A; Sharp, A; Welti, JC; Neeb, A; Raj, GV; Luo, J; Plymate, SR; de Bono, JS (2018-11)
      Androgen receptor (AR) splice variants (AR-Vs) have been implicated in the development and progression of metastatic prostate cancer. AR-Vs are truncated isoforms of the AR, a subset of which lack a ligand-binding domain ...
    • Ambiguity in a masculine world: Being a BRCA1/2 mutation carrier and a man with prostate cancer. 

      Moynihan, C; Bancroft, EK; Mitra, A; Ardern-Jones, A; Castro, E; Page, EC; Eeles, RA (2017-11)
      OBJECTIVE:Increased risk of prostate cancer (PCa) is observed in men with BRCA1/BRCA2 mutations. Sex and gender are key determinants of health and disease although unequal care exists between the sexes. Stereotypical male ...
    • Analyses of DNA adducts formed by ochratoxin A and aristolochic acid in patients with Chinese herbs nephropathy. 

      Arlt, VM; Pfohl-Leszkowicz, A; Cosyns, J; Schmeiser, HH (2001-07)
      Chinese herbs nephropathy (CHN), a unique type of nephropathy has been associated with the intake of weight-reducing pills containing the Chinese herb Aristolochia fangchi. Moreover, an association between the use of A. ...
    • Analysis of 153 115 patients with hematological malignancies refines the spectrum of familial risk. 

      Sud, A; Chattopadhyay, S; Thomsen, H; Sundquist, K; Sundquist, J; Houlston, RS; Hemminki, K (2019-09)
      Estimating familial cancer risks is clinically important in being able to discriminate between individuals in the population at differing risk for malignancy. To gain insight into the familial risk for the different ...
    • Analysis of Over 140,000 European Descendants Identifies Genetically Predicted Blood Protein Biomarkers Associated with Prostate Cancer Risk. 

      Wu, L; Shu, X; Bao, J; Guo, X; Kote-Jarai, Z; Haiman, CA; Eeles, RA; Zheng, W; PRACTICAL, CRUK, BPC3, CAPS, PEGASUS Consortia (2019-09)
      Several blood protein biomarkers have been associated with prostate cancer risk. However, most studies assessed only a small number of biomarkers and/or included a small sample size. To identify novel protein biomarkers ...
    • Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer. 

      Welti, J; Rodrigues, DN; Sharp, A; Sun, S; Lorente, D; Riisnaes, R; Figueiredo, I; Zafeiriou, Z; Rescigno, P; de Bono, JS; Plymate, SR (2016-10)
      BACKGROUND:The androgen receptor splice variant-7 (AR-V7) has been implicated in the development of castration-resistant prostate cancer (CRPC) and resistance to abiraterone and enzalutamide. OBJECTIVE:To develop a validated ...
    • Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands. 

      Boon, E; van Boxtel, W; Buter, J; Baatenburg de Jong, RJ; van Es, RJJ; Bel, M; Fiets, E; Oosting, SF; Slingerland, M; Hoeben, A; Tesselaar, MET; Jonker, MA; Flucke, UE; Nationwide Network and Registry of Histopathology and Cytopathology (PALGA) Group; van der Graaf, WTA; van Herpen, CML (2018-03)
      BACKGROUND:Salivary duct carcinoma, an aggressive subtype of salivary gland cancer, is mostly androgen receptor-positive. Only limited data are available on androgen deprivation therapy (ADT). METHODS:Patients with advanced ...